SMMT is the ticker symbol for Summit Therapeutics Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks SMMT with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is SMMT a good stock to buy?

SMMT is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/SMMT.

Where does 13F Pro source SMMT data?

All Summit Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Summit Therapeutics Inc. files with the SEC under CIK 1599298. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Summit Therapeutics Inc.(SMMT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Summit Therapeutics Inc. (SMMT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SMMT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Summit Therapeutics Inc. reports net income of $-215.7M, free cash flow of $-142.0M. Top institutional holders of SMMT by reported 13-F value include BAKER BROS. ADVISORS, FMR, STATE STREET, based on the most recent SEC filings. SMMT trades on the Nasdaq exchange and files with the SEC under CIK 1599298. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SMMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Summit Therapeutics Inc. directly from SEC EDGAR.

Net Income

$-215.7M

Free Cash Flow

$-142.0M

SMMT key financials by period

Summit Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2022	10-K	$705.0K	$-78.8M	—
FY 2021	10-K/A	$1.8M	$-88.6M	—
FY 2020	10-K/A	$860.0K	$-52.7M	—
FY 2019	10-K	$743.0K	$-29.1M	—

Institutions holding SMMT

Institutional investors reporting a position in Summit Therapeutics Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
BAKER BROS. ADVISORS	32,786,348	$477.7M	2026-06-30
FMR	10,043,947	$146.3M	2026-06-30
STATE STREET	9,536,796	$139.0M	2026-06-30
BlackRock	9,529,041	$138.8M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	5,734,484	$83.6M	2026-06-30
UBS Group AG	5,233,798	$76.3M	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	5,042,190	$73.5M	2026-06-30
GOLDMAN SACHS GROUP	4,513,399	$65.8M	2026-06-30
PRICE T ROWE ASSOCIATES	3,893,820	$56.7M	2026-06-30
Point72 Asset Management, L.P.	3,697,803	$53.9M	2026-06-30

SEC EDGAR: CIK 1599298 →

Summit Therapeutics Inc.

SMMT

NasdaqLarge CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.